File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Conference Paper: Pharmacogenetics of weight gain in young people treated with Risperidone

TitlePharmacogenetics of weight gain in young people treated with Risperidone
Authors
Keywordsrisperidone
weight gain
children
pharmacogenetics
Issue Date2013
PublisherThe Pharmaceutical Society of Hong Kong. The Journal's web site is located at http://www.pshk.hk/main.php?id=62
Citation
The 8th Asian Conference on Pharmacoepidemiology (ACPE 2013), Hong Kong, China, 25-27 October 2013. In Hong Kong Pharmaceutical Journal, 2013, v. 20 n. 3, p. 142 How to Cite?
AbstractAim/Objective: To investigate the association between weight gain and specifi c genotypes in young people treated with risperidone. • To genotype three specifi c genes (HTR2c receptors, LEP and LEPR) which are thought to be likely candidates for association between risperidone and weight gain. • To assess the association between the genotypes of each gene and weight gain. Methods: A retrospective multicentre study was conducted in outpatient mental health clinics/hospitals in the UK and the Kingdom of Saudi Arabia. Analysis was undertaken using TaqMan technology for genotyping and for statistical analysis, SPSS 21 for Windows was used. Results: 200 patients were genotyped, and 197 genotypes were successfully “Called”. All genotyping passed Hardy-Weinberg checking. For all genes, we found no signifi cant association with risperidone –induced weight gain after controlling for baseline weight, age, diagnosis and ethnicity. Signifi cant association was found between baseline BMI-Z, patients with a lower baseline BMI gaining more weight; age at onset of risperidone treatment (p<0.005), younger patients tending to gain more weight (p<0.005) for all 5 SNPs tested, and a signifi cant association between weight gain and ethnicity, individuals of Arab origin being more likely to gain weight than Caucasians (p=0.011- p=0,014) for all SNPs. No association with gender was found for any genotypes. Conclusion: In this sample there does not appear to have been a signifi cant association with risperidone-induced weight gain and any of the genotypes tested. Further studies exploring ethnic variations and age at onset of treatment are warranted, and a larger sample may have yielded more signifi cant results.
DescriptionConference Theme: Applying pharmacoepidemiology to improve health care in Asia
Oral Presentation - Paediatrics – Mental and General Health
Persistent Identifierhttp://hdl.handle.net/10722/204455
ISSN

 

DC FieldValueLanguage
dc.contributor.authorAlmandil, NBen_US
dc.contributor.authorOhlsen, Ren_US
dc.contributor.authorMurray, MLen_US
dc.contributor.authorBesag, FMCen_US
dc.contributor.authorAitchison, KJen_US
dc.contributor.authorWong, ICKen_US
dc.date.accessioned2014-09-19T23:52:22Z-
dc.date.available2014-09-19T23:52:22Z-
dc.date.issued2013en_US
dc.identifier.citationThe 8th Asian Conference on Pharmacoepidemiology (ACPE 2013), Hong Kong, China, 25-27 October 2013. In Hong Kong Pharmaceutical Journal, 2013, v. 20 n. 3, p. 142en_US
dc.identifier.issn1727-2874-
dc.identifier.urihttp://hdl.handle.net/10722/204455-
dc.descriptionConference Theme: Applying pharmacoepidemiology to improve health care in Asia-
dc.descriptionOral Presentation - Paediatrics – Mental and General Health-
dc.description.abstractAim/Objective: To investigate the association between weight gain and specifi c genotypes in young people treated with risperidone. • To genotype three specifi c genes (HTR2c receptors, LEP and LEPR) which are thought to be likely candidates for association between risperidone and weight gain. • To assess the association between the genotypes of each gene and weight gain. Methods: A retrospective multicentre study was conducted in outpatient mental health clinics/hospitals in the UK and the Kingdom of Saudi Arabia. Analysis was undertaken using TaqMan technology for genotyping and for statistical analysis, SPSS 21 for Windows was used. Results: 200 patients were genotyped, and 197 genotypes were successfully “Called”. All genotyping passed Hardy-Weinberg checking. For all genes, we found no signifi cant association with risperidone –induced weight gain after controlling for baseline weight, age, diagnosis and ethnicity. Signifi cant association was found between baseline BMI-Z, patients with a lower baseline BMI gaining more weight; age at onset of risperidone treatment (p<0.005), younger patients tending to gain more weight (p<0.005) for all 5 SNPs tested, and a signifi cant association between weight gain and ethnicity, individuals of Arab origin being more likely to gain weight than Caucasians (p=0.011- p=0,014) for all SNPs. No association with gender was found for any genotypes. Conclusion: In this sample there does not appear to have been a signifi cant association with risperidone-induced weight gain and any of the genotypes tested. Further studies exploring ethnic variations and age at onset of treatment are warranted, and a larger sample may have yielded more signifi cant results.-
dc.languageengen_US
dc.publisherThe Pharmaceutical Society of Hong Kong. The Journal's web site is located at http://www.pshk.hk/main.php?id=62-
dc.relation.ispartofHong Kong Pharmaceutical Journalen_US
dc.subjectrisperidone-
dc.subjectweight gain-
dc.subjectchildren-
dc.subjectpharmacogenetics-
dc.titlePharmacogenetics of weight gain in young people treated with Risperidoneen_US
dc.typeConference_Paperen_US
dc.identifier.emailWong, ICK: wongick@hku.hken_US
dc.identifier.authorityWong, ICK=rp01480en_US
dc.identifier.hkuros239882en_US
dc.identifier.volume20en_US
dc.identifier.issue3en_US
dc.identifier.spage142en_US
dc.identifier.epage142en_US
dc.publisher.placeHong Kong-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats